Zobrazeno 1 - 10
of 778
pro vyhledávání: '"Richard E Champlin"'
Autor:
Laura K. Whited, Jose Banchs, Richard E. Champlin, Uday R. Popat, Elizabeth J. Shpall, Gabriela Rondon, Rima M. Saliba, Jason Yeh
Publikováno v:
Blood Advances
Key Points The incidence of acute cardiac toxicity remains low and manageable after matched allo-HCT in the era of PTCy prophylaxis.Older age, hypertension, arrhythmia, diabetes, and cardiac comorbidities increase this risk of cardiac toxicity but PT
Autor:
P. Andrew Futreal, Ken Furudate, Marina Konopleva, Sanam Loghavi, Guillermo Garcia-Manero, Sa A. Wang, Yuya Sasaki, Gheath Alatrash, Musa Yilmaz, Koji Sasaki, Naveen Pemmaraju, Latasha Little, Tapan M. Kadia, Koichi Takahashi, Farhad Ravandi, Kiyomi Morita, Curtis Gumbs, Jairo Matthews, Feng Wang, Hagop M. Kantarjian, Courtney D. DiNardo, Richard E. Champlin, Naval Daver, Tomoyuki Tanaka
Publikováno v:
Blood
Introduction While clonal hematopoiesis (CH) can precede the development of AML, preleukemic CH can persist after attaining remission. In rare cases, non-leukemic CH can also emerge after remission. Long-term clonal dynamics of persistent CH or emerg
Autor:
Stefan O. Ciurea, Piyanuch Kongtim, Gabriela Rondon, Salman Otoukesh, Stephen J. Forman, Richard E. Champlin, Julianne Chen, Auayporn Nademanee, Michiko Taniguchi, Kai Cao, Ketevan Gendzekhadze, Fleur M. Aung, Jun Zou, Monzr M. Al Malki
Publikováno v:
Blood Advances. 5:4031-4043
Donor-specific anti-HLA antibodies (DSAs) are a major cause of engraftment failure in patients receiving haploidentical stem cell transplantation (HaploSCT). Effective treatments are needed for these patients, who often have no other donor options an
Autor:
Jeremy Ramdial, Sheeba K. Thomas, Elizabeth J. Shpall, Hans C. Lee, Richard E. Champlin, Muzaffar H. Qazilbash, Samer A. Srour, Qaiser Bashir, Ruby Delgado, Neeraj Saini, Yago Nieto, Elisabet E. Manasanch, Jin Im, Krina K. Patel, Uday R. Popat, Denái R. Milton, Robert Z. Orlowski, Greg Kaufman, Donna M. Weber, May Daher, Chitra Hosing
Publikováno v:
Haematologica
Autor:
David Marin, Elias Jabbour, Denái R. Milton, Amanda Olson, Gabriela Rondon, Jin S. Im, Rohtesh S. Mehta, Uday R. Popat, May Daher, Felipe Samaniego, Loretta J. Nastoupil, Neeraj Saini, Celina Ledesma, Paolo Anderlini, Muzaffar H. Qazilbash, Qaiser Bashir, Issa F. Khouri, Alison M. Gulbis, Richard E. Champlin, L. Jeffrey Medeiros, Swaminathan P. Iyer
Publikováno v:
Clinical Cancer Research. 27:5847-5856
Purpose: To compare outcomes between patients with relapsed follicular lymphoma who received a nonmyeloablative allogeneic stem cell transplant (alloSCT) and those who received an autologous transplant (autoSCT). Patients and Methods: We evaluated 19
Autor:
Jillian R. Gunther, Bouthaina S. Dabaja, Swaminathan Padmanabhan Iyer, Richard E. Champlin, Melissa Barnett, Hubert H. Chuang, Sajad Khazal, Borje S. Andersson, Benigno C. Valdez, Neeraj Saini, Terri Lynn Shigle, Branko Cuglievan, Ranjit Nair, Chitra Hosing, Amin M. Alousi, Hun Lee, Kris Michael Mahadeo, Paolo Anderlini, Samer A. Srour, Sairah Ahmed, Simrit Parmar, Yago Nieto, Elizabeth J. Shpall, Raphael E Steiner, Muzaffar H. Qazilbash, Chelsea C. Pinnix, Uday R. Popat, Alison M. Gulbis, Partow Kebriaei, Katayoun Rezvani, Roy B. Jones, Stephen K. Gruschkus, Jeremy Ramdial
Publikováno v:
Haematologica. 107:899-908
High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment for chemosensitive relapsed classical Hodgkin lymphoma, although outcomes of high-risk relapse (HRR) patients remain suboptimal. We retrospectively analyzed a
Autor:
Muzaffar H. Qazilbash, Samer A. Srour, Borje S. Andersson, Jeremy Ramdial, Betul Oran, Rohtesh S. Mehta, Uday R. Popat, Partow Kebriaei, Chitra Hosing, Amanda Olson, Richard E. Champlin, Rima M. Saliba, Qaiser Bashir, Amin M. Alousi
Publikováno v:
Bone Marrow Transplantation. 56:2005-2012
Despite low nonrelapse mortality (NRM) at day 100 after allogeneic hematopoietic cell transplantation (HCT), NRM at 1 year remains substantial. In this study, we retrospectively analyzed 199 patients who were treated on a phase II clinical trial asse
Autor:
Betul Oran, Ben C. Valdez, Partow Kebriaei, Rohtesh S. Mehta, Katy Rezvani, David Marin, Julianne Chen, Elizabeth J. Shpall, Amin M. Alousi, Uday R. Popat, Richard E. Champlin, Qaiser Bashir, Rima M. Saliba, Amanda Olson, Stefan O. Ciurea, Borje S. Andersson, Chitra Hosing
Publikováno v:
Cancer. 127:1598-1605
Background A myeloablative conditioning regimen can be safely given to older patients and those with comorbidities without increasing nonrelapse mortality (NRM) by fractionating the dose of intravenous busulfan. How this approach compares in efficacy
Autor:
P. Anderlini, David Marin, Rohtesh S. Mehta, Roy B. Jones, Muzaffar H. Qazilbash, Daniel R. Couriel, Kayo Kondo, U. Popat, Bethany J. Overman, Katy Rezvani, Issa F. Khouri, Betul Oran, Stefan O. Ciurea, Amin M. Alousi, Richard E. Champlin, Chitra Hosing, Gabriela Rondon, Elizabeth J. Shpall, Roland L. Bassett, Partow Kebriaei
Publikováno v:
Bone Marrow Transplantation. 56:1316-1324
Steroids remain the initial therapy for acute graft-vs.-host disease (AGVHD). Strategies to improve response and minimize steroid exposure are needed. We report results of a randomized, adaptive, Bayesian-designed, phase II trial of prednisone with o
Autor:
Glenda Woodworth, Ruitao Lin, Richard E. Champlin, Peter F. Thall, Amin M. Alousi, Chitra Hosing, Guillermo Garcia-Manero, Marcos de Lima, Sergio Giralt, Uday R. Popat, Betul Oran, Gabriela Rondon
Publikováno v:
Blood Advances. 4:5580-5588
This study investigated the efficacy and safety of azacitidine maintenance in the posttransplant setting based on the encouraging phase 1/2 reports for azacitidine maintenance in patients with acute myeloid leukemia/myelodysplastic syndrome (AML/MDS)